Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment (Q38152329)

29 August 2017

Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment (English)

1 reference

29 August 2017

1 reference

Gail D Anderson

1

1 reference

29 August 2017

Shahin Hakimian

series ordinal

2

1 reference

29 August 2017

language of work or name

1 reference

1 January 2014

1 reference

Clinical Pharmacokinetics

29 August 2017

1 reference

29 August 2017

53

1 reference

29 August 2017

29-49

1 reference

29 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-013-0107-0

29 August 2017

0 references

cites work

Drug dosing in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Changes in plasma protein binding have little clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Optimizing pediatric dosing: a developmental pharmacologic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Effects of renal failure on drug transport and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Reporting estimated GFR: a laboratory perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

A new equation to estimate glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

A systematic comparison of cockcroft-gault and modification of diet in renal disease equations for classification of kidney dysfunction and dosage adjustment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Clinical significance of pharmacokinetic models of hepatic elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Effects of aging and liver disease on disposition of lorazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Conjugation pathways in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Clinical pharmacokinetics of pregabalin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics of pregabalin in subjects with various degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

The pharmacologic basis of antiepileptic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

21 January 2018

Vigabatrin: 2008 update

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Vigabatrin. Clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics of a Single Oral Dose of Clobazam in Patients with Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Clinical Pharmacokinetics of Diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

The effects of age and liver disease on the disposition and elimination of diazepam in adult man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics of diazepam in disordered liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Influence of cirrhosis on lamotrigine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Clinical Pharmacokinetics of Oxazepam and Lorazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics of midazolam in anaesthetized cirrhotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Diphenylhydantoin Metabolism in Uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Michaelis-Menten kinetics of stiripentol in normal humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Tiagabine: a novel antiepileptic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Disposition of valproic acid in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Novel medications for epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics and drug interactions of eslicarbazepine acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Single-dose pharmacokinetics of felbamate in patients with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics and metabolism of 14 C-levetiracetam, a new antiepileptic agent, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Use of levetiracetam in special populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Clinical pharmacokinetics of oxcarbazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Novel treatment options for epilepsy: focus on perampanel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Clinical pharmacokinetics of retigabine/ezogabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Pharmacokinetics and drug interactions with zonisamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Idiosyncratic adverse reactions to antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Cross-sensitivity of skin rashes with antiepileptic drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Valproic acid hepatic fatalities. III. U.S. experience since 1986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Risk factors for hyperammonemia in pediatric patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

The effects of sodium valproate on the renal function of children with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Renal tubular function in patients receiving anticonvulsant therapy: a long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Topiramate increases biochemical risk of nephrolithiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Incidence of kidney stones with topiramate treatment in pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Urine stone formation during treatment with zonisamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Influence of acute viral hepatitis on phenytoin kinetics and protein binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0107-0

Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite

21 January 2018

1 reference

12 December 2020

Antiepileptic drug treatment: new drugs and new strategies

1 reference

12 December 2020

Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis

1 reference

12 December 2020

Pharmacokinetics of vigabatrin: implications of creatinine clearance

1 reference

12 December 2020

Human brain phenytoin: correlation with unbound and total serum concentrations

1 reference

12 December 2020

The protein binding of diazepam and N-demethyldiazepam in patients with poor renal function

1 reference

12 December 2020

Accuracy of two equations in determining normalized phenytoin concentrations.

1 reference

12 December 2020

The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites

1 reference

12 December 2020

Liver disease selectively modulates cytochrome P450--mediated metabolism

1 reference

12 December 2020

The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects.

1 reference

12 December 2020

Altered protein binding of diphenylhydamtoin in uremic plasma

1 reference

12 December 2020

Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease

1 reference

12 December 2020

Is glucuronidation truly preserved in patients with liver disease?

1 reference

12 December 2020

In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19.

1 reference

12 December 2020

Comparison of 99mTc-DTPA renal dynamic imaging with modified MDRD equation for glomerular filtration rate estimation in Chinese patients in different stages of chronic kidney disease.

1 reference

12 December 2020

Current oral and non-oral routes of antiepileptic drug delivery

1 reference

12 December 2020

Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine

1 reference

12 December 2020

Protein binding of valproic acid in uremic patients

1 reference

12 December 2020

Plasma protein binding of clonazepam in hepatic and renal insufficiency and after hemodialysis

1 reference

12 December 2020

The effect of liver disease in man on the disposition of phenobarbital

1 reference

12 December 2020

Valproate hepatotoxicity: a review and report of two instances in adults

1 reference

12 December 2020

Zonisamide - induced urinary lithiasis in patients with intractable epilepsy

1 reference

12 December 2020

Ibuprofen and sulindac kinetics in alcoholic liver disease

1 reference

12 December 2020

Pharmacokinetics of gabapentin in subjects with various degrees of renal function

1 reference

12 December 2020

The pharmacokinetics of midazolam in chronic renal failure patients.

1 reference

12 December 2020

Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation

1 reference

12 December 2020

Evaluation of renal tubular function in children taking anti-epileptic treatment

1 reference

12 December 2020

Effect of renal impairment and hemodialysis on lorazepam kinetics

1 reference

12 December 2020

Hemodialysis clearance of ethosuximide in patients with chronic renal disease

1 reference

12 December 2020

[Anti-rheumatic therapy in patients with liver diseases. Plasma levels of diclofenac and elimination of diclofenac and metabolites in urine of patients with liver disease]

1 reference

12 December 2020

Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate

1 reference

12 December 2020

Factors influencing diazepam pharmacokinetics: age, sex, and liver disease.

1 reference

12 December 2020

Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers

1 reference

12 December 2020

Carbamazepine clearance in hemodialysis and hemoperfusion

1 reference

12 December 2020

Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function

1 reference

12 December 2020

Disposition of gabapentin in anuric subjects on hemodialysis

1 reference

12 December 2020

Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples

1 reference

12 December 2020

The metabolic fate of stiripentol in man.

1 reference

12 December 2020

Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia.

1 reference

12 December 2020

Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide

1 reference

12 December 2020

Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure

1 reference

12 December 2020

Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction.

1 reference

12 December 2020

Variable free and total valproic acid concentrations in sole- and multi-drug therapy

1 reference

12 December 2020

Clinical pharmacokinetics of gabapentin

1 reference

12 December 2020

Metabolism of retigabine (D-23129), a novel anticonvulsant

1 reference

12 December 2020

Protein binding of valproic acid in the presence of elevated free fatty acids in patient and normal human serum

1 reference

12 December 2020

The absorption and excretion of ethosuximide

1 reference

12 December 2020

Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients

1 reference

12 December 2020

10.1007/S40262-013-0107-0

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference